Q2 EPS Forecast for Mineralys Therapeutics Raised by Analyst

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) – Equities researchers at HC Wainwright increased their Q2 2025 earnings per share (EPS) estimates for shares of Mineralys Therapeutics in a report released on Tuesday, May 13th. HC Wainwright analyst M. Caufield now expects that the company will post earnings per share of ($0.85) for the quarter, up from their prior forecast of ($0.88). HC Wainwright has a “Buy” rating and a $42.00 price target on the stock. The consensus estimate for Mineralys Therapeutics’ current full-year earnings is ($4.23) per share. HC Wainwright also issued estimates for Mineralys Therapeutics’ Q3 2025 earnings at ($0.92) EPS, Q4 2025 earnings at ($1.00) EPS, FY2025 earnings at ($3.59) EPS, FY2026 earnings at ($3.22) EPS, FY2027 earnings at ($3.50) EPS, FY2028 earnings at ($1.75) EPS and FY2029 earnings at $1.28 EPS.

Several other research firms have also commented on MLYS. Guggenheim reaffirmed a “buy” rating on shares of Mineralys Therapeutics in a report on Monday, February 24th. The Goldman Sachs Group decreased their price objective on Mineralys Therapeutics from $28.00 to $24.00 and set a “buy” rating for the company in a report on Thursday, February 13th.

Mineralys Therapeutics Trading Down 0.5%

MLYS opened at $15.11 on Thursday. The firm has a 50 day moving average of $14.26 and a two-hundred day moving average of $12.46. Mineralys Therapeutics has a 12-month low of $8.24 and a 12-month high of $18.38. The firm has a market capitalization of $980.28 million, a PE ratio of -4.15 and a beta of -0.30.

Mineralys Therapeutics (NASDAQ:MLYS) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.02) by $0.23.

Insider Transactions at Mineralys Therapeutics

In other Mineralys Therapeutics news, CFO Adam Scott Levy sold 10,757 shares of Mineralys Therapeutics stock in a transaction on Friday, April 11th. The shares were sold at an average price of $12.06, for a total value of $129,729.42. Following the completion of the transaction, the chief financial officer now owns 215,340 shares of the company’s stock, valued at approximately $2,597,000.40. The trade was a 4.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider David Malcom Rodman sold 11,366 shares of the stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $14.53, for a total value of $165,147.98. Following the transaction, the insider now owns 111,686 shares in the company, valued at $1,622,797.58. This represents a 9.24% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 93,213 shares of company stock valued at $1,360,567 in the last 90 days. 25.56% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Mineralys Therapeutics

Several institutional investors have recently bought and sold shares of the company. Trexquant Investment LP acquired a new stake in shares of Mineralys Therapeutics in the first quarter valued at about $2,009,000. 22NW LP acquired a new position in Mineralys Therapeutics in the first quarter valued at about $7,326,000. Pale Fire Capital SE boosted its position in shares of Mineralys Therapeutics by 191.8% during the first quarter. Pale Fire Capital SE now owns 399,498 shares of the company’s stock worth $6,344,000 after buying an additional 262,601 shares during the period. AlphaQuest LLC boosted its holdings in Mineralys Therapeutics by 4.6% during the 1st quarter. AlphaQuest LLC now owns 15,925 shares of the company’s stock valued at $253,000 after acquiring an additional 703 shares during the period. Finally, Monashee Investment Management LLC acquired a new stake in shares of Mineralys Therapeutics during the first quarter worth about $1,786,000. 84.46% of the stock is currently owned by institutional investors and hedge funds.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.